Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Experimental neurology - 1 Nov 2018

Kelly Kaela, Wang Shijie, Boddu Ravindra, Liu Zhiyong, Moukha-Chafiq Omar, Augelli-Szafran Corinne, West Andrew B

Abstract excerpt

The G2019S mutation in LRRK2 is one of the most common known genetic causes of neurodegeneration and Parkinson disease (PD). LRRK2 mutations are thought to enhance LRRK2 kinase activity. Efficacious small molecule LRRK2 kinase inhibitors with favorable drug properties have recently been developed for pre-clinical studies in rodent models, and inhibitors have advanced to safety trials in humans. Rats that express...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycine
Share to Indazoles
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lysosomes

Share to Mass Spectrometry

Share to Pyrimidines

Share to Rats, Transgenic

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 30048714
DOI: 10.1016/j.expneurol.2018.07.012
PMCID: PMC7041630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.PMID 30048714Read ↗

Preclinical Modeling of Chronic Inhibition of the Parkinson’s Disease Associated Kinase LRRK2 Reveals Altered Function of the Endolysosomal System in VivoSemantic proximity Read ↗

Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivoSemantic proximity Read ↗

G2019S LRRK2 Kinase Inhibition in Heterozygous Mice Avoids Lung Phenotype Observed with Inhibition of WT LRRK2.Semantic proximity Read ↗

Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activitySemantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pRab10Semantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10Semantic proximity Read ↗

Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkersSemantic proximity Read ↗

Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s diseaseSemantic proximity Read ↗

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.Semantic proximity Read ↗

Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson's disease.Semantic proximity Read ↗

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spreadSemantic proximity Read ↗

Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.